Empreses emergents
2015
AELIX THERAPEUTICS SLDesenvolupament de noves vacunes per curar la infecció pel VIH immunogen HTI: una nova vacuna terapèutica contra el VIH
Adreça
Carrer de Baldiri Reixac 10, 08028 Barcelona, Espanya
Dades financeres
| Data | Inversors | Quantitat | Etapa | |
| Sep 2021 | 1.700.000 € | Seed | ||
| Jan 2016 | 10.000.000 € | Series A |
Resum financer
Encara no s'han registrat ingressos
Propietat CERCA
Badalona, Spain
1995
Institut de Recerca de la Sida (IRSICAIXA)
Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
AELIX Therapeutics is a biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be used in cure/eradication strategies. Aelix Therapeutics is a spin-off of HIVACAT, a Catalan public-private consortium conducting cutting-edge research in this field.
Descripció del producte
The unique and proprietary HTI immunogen sequence was designed by AELIX Therapeutics’ founders and is being delivered to the body by multiple viral and non-viral vectors. GMP-grade clinical trial supplies have been manufactured. AELIX-002, the first clinical trial run by the company, started in September 2017. It is a phase-I randomised, double-blind, placebo-controlled safety, tolerability, and immunogenicity study of the HTI vaccine in early diagnosed, early treated HIV-infected individuals. It evaluates a therapeutic, heterologous prime-boost vaccination regimen using DNA plasmids and an MVA (Modified-Virus-Ankara) vector in the prime phase and a Chimpanzee-Adenovirus (ChAd) and MVA vectors in the booster phase. In a first phase, 15 HIV-infected individuals were included in the trial. Starting in June 2018, 30 additional participants were added to the study, which is still ongoing. After vaccination, the participants are subjected to an analytical anti-retroviral treatment interruption (ATI) to assess their capacity to control viral replication in the absence of anti-retroviral medication. Data from this trial is expected in March 2021.
Empresa tancada o sortida